Herpetic Keratitis Market Size

DelveInsight's 'Herpetic Keratitis - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Herpetic Keratitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Herpetic Keratitis from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2017-2028

Herpetic Keratitis - Disease Understanding and Treatment Algorithm

The DelveInsight Herpetic Keratitis market report gives the thorough understanding of the Herpetic Keratitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Herpetic Keratitis in the US, Europe, and Japan.


Herpetic Keratitis Epidemiology

The Herpetic Keratitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases, diagnosed cases, type specific incident cases, and incident cases based on Metaherpetic Manifestations) scenario of Herpetic Keratitis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Herpetic Keratitis in 7 MM was found to be 166,057, in the year 2017.

Herpetic Keratitis Drug Chapters

This segment of the Herpetic Keratitis report encloses the detailed analysis of marketed drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment (inclusive of the antivirals and corticosteroids, which includes both topical as well as oral). The antiviral agents employed against HSV are primarily nucleoside analogs which function by competitive inhibition, becoming incorporated into viral DNA within infected cells. Detailed chapter for Viroptic (Trifluridine), a synthetic pyrimidine nucleoside approved by the US FDA since 1980 has been in continuous use since the past three decades and is the most widely used topical antiviral agent for treatment of HSV keratitis in the US and topical antiviral agent Zirgan (Ganciclovir), which is a synthetic purine nucleoside, and an analog of guanosine have been covered in the report. However, the pipeline does not represent a particularly encouraging scenario with no novel upcoming drugs during the forecast period [2019-2028].


Herpetic Keratitis Market Outlook

The Herpetic Keratitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Herpetic Keratitis in 7MM was found to be USD 68.3 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.

Herpetic Keratitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Herpetic Keratitis Report Insights

• Patient Population

• Therapeutic Approaches

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Herpetic Keratitis Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition


Herpetic Keratitis Report Assessment

• Current Treatment Practices

• Unmet Needs

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Herpetic Keratitis market

• Organize sales and marketing efforts by identifying the best opportunities for Herpetic Keratitis market

• To understand the future market competition in the Herpetic Keratitis market.

1. Key Insights

2. Herpetic Keratitis Market Overview at a Glance

2.1. Market Share (%) Distribution of Herpetic Keratitis in 2017

2.2. Market Share (%) Distribution of Herpetic Keratitis in 2028

3. Disease Background and Overview

3.1. Introduction

3.2. Symptoms and Clinical Manifestations

3.3. Herpes Antiviral Therapy

3.4. Causes of Herpetic Keratitis

3.5. Immune Control of Corneal Infection

3.5.1. Role of Innate immunity in controlling HSV-1 replication in the corneal epithelium

3.5.2. Role of adaptive immunity in HSV-1 clearance from the cornea

3.6. Role of vascularization in HSK

3.7. Leukocytic Involvement in HSK

3.8. HSV-1 latency

3.8.1. Maintenance and reactivation from latency

3.8.2. Immune control of HSV-1 reactivation from latency

3.9. Pathophysiology

3.10. Diagnosis

3.11. Risk Factors

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7MM Total Patient Population of Herpetic Keratitis

5. Country Wise-Epidemiology of Herpetic Keratitis

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Total Incident Population of Herpetic Keratitis in the United States

5.1.3. Total Diagnosed Cases of Herpetic Keratitis in the United States

5.1.4. Incidence of Herpetic Keratitis by types in the United States

5.1.5. Metaherpetic Manifestations of Herpetic Keratitis in the United States

5.2. EU5 Countries

5.2.1. Assumptions and Rationale

5.3. Germany

5.3.1. Total Incident Population of Herpetic Keratitis in Germany

5.3.2. Total Diagnosed Cases of Herpetic Keratitis in Germany

5.3.3. Incidence of Herpetic Keratitis by types in Germany

5.3.4. Metaherpetic Manifestations of Herpetic Keratitis in Germany

5.4. France

5.4.1. Total Incident Population of Herpetic Keratitis in France

5.4.2. Total Diagnosed Cases of Herpetic Keratitis in France

5.4.3. Incidence of Herpetic Keratitis by types in France

5.4.4. Metaherpetic Manifestations of Herpetic Keratitis in France

5.5. Italy

5.5.1. Total Incident Population of Herpetic Keratitis in Italy

5.5.2. Total Diagnosed Cases of Herpetic Keratitis in Italy

5.5.3. Incidence of Herpetic Keratitis by types in Italy

5.5.4. Metaherpetic Manifestations of Herpetic Keratitis in Italy

5.6. Spain

5.6.1. Total Incident Population of Herpetic Keratitis in Spain

5.6.2. Total Diagnosed Cases of Herpetic Keratitis in Spain

5.6.3. Incidence of Herpetic Keratitis by types in Spain

5.6.4. Metaherpetic Manifestations of Herpetic Keratitis in Spain

5.7. United Kingdom

5.7.1. Total Incident Population of Herpetic Keratitis in UK

5.7.2. Total Diagnosed Cases of Herpetic Keratitis in UK

5.7.3. Incidence of Herpetic Keratitis by types in UK

5.7.4. Metaherpetic Manifestations of Herpetic Keratitis in UK

5.8. Japan

5.8.1. Assumptions and Rationale

5.8.2. Total Incident Population of Herpetic Keratitis in Japan

5.8.3. Total Diagnosed Cases of Herpetic Keratitis in Japan

5.8.4. Incidence of Herpetic Keratitis by types in Japan

5.8.5. Metaherpetic Manifestations of Herpetic Keratitis in Japan

5.9. Treatment

5.9.1. Medical Therapy

5.9.2. Antiviral prophylaxis

5.9.3. Surgical Therapy

5.10. U.S. Guidelines

5.10.1. Local Susceptibility of Host Tissue

5.11. Europe Guidelines

5.12. Management of Herpetic Keratitis

6. Unmet Needs

7. Marketed Drugs

7.1. Zirgan: Sirion Therapeutics

7.1.1. Product Description

7.1.2. Regulatory Milestones

7.1.3. Product Profile

7.1.4. Safety and Efficacy of Zirgan

7.1.5. Side effects of Zirgan

7.2. Viroptic: Pfizer

7.2.1. Product Description

7.2.2. Regulatory Milestones

7.2.3. Product Profile

7.2.4. Safety and Efficacy of Viroptic

7.2.5. Side effects of Viroptic

8. Herpetic Keratitis: 7 Major Market Analysis

8.1. Key Findings

8.2. Market Size of Herpetic Keratitis in 7MM

9. The United States Market Outlook

9.1. United States Market Size

9.1.1. Total Market size of Herpetic Keratitis

9.1.2. Market Size by Line of Therapies

10. EU-5 Countries: Market Outlook

10.1. Germany

10.1.1. Total Market size of Herpetic Keratitis in Germany

10.1.2. Market Size by Line of Therapies

10.2. France

10.2.1. Total Market Size of Herpetic Keratitis

10.2.2. Market Size by Line of Therapies

10.3. Italy

10.3.1. Total Market Size of Herpetic Keratitis

10.3.2. Market Size by Line of Therapies

10.4. Spain

10.4.1. Total Market Size of Herpetic Keratitis

10.4.2. Market Size by Line of Therapies

10.5. The United Kingdom

10.5.1. Total Market Size of Herpetic Keratitis

10.5.2. Market Size by Line of Therapies

11. Japan: Market Outlook

11.1. Japan market Size

11.1.1. Total Market Size of Herpetic Keratitis

11.1.2. Market Size by Line of Therapies

12. Market Drivers

13. Market Barriers

14. Appendix

14.1. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

Table 1: Total Population of Herpetic Keratitis in the 7MM (2017-2028)

Table 2: Total Incident Population of Herpetic Keratitis in the United States (2017-2028)

Table 3: Total Diagnosed cases of Herpetic Keratitis in the United States (2017-2028)

Table 4: Incidence of Herpetic Keratitis by types in the United States (2017-2028)

Table 5: Incidence of Epithelial Keratitis by sub-types in the United States (2017-2028)

Table 6: Incidence of Stromal Keratitis by sub-types in the United States (2017-2028)

Table 7: Metaherpetic Manifestations of Herpetic Keratitis in the United States (2017-2028)

Table 8: Total Incident Population of Herpetic Keratitis in Germany (2017-2028)

Table 9: Total Diagnosed cases of Herpetic Keratitis in Germany (2017-2028)

Table 10: Incidence of Herpetic Keratitis by types in Germany (2017-2028)

Table 11: Incidence of Epithelial Keratitis by sub-types in Germany (2017-2028)

Table 12: Incidence of Stromal Keratitis by sub-types in Germany (2017-2028)

Table 13: Metaherpetic Manifestations of Herpetic Keratitis in Germany (2017-2028)

Table 14: Total Incident Population of Herpetic Keratitis in France (2017-2028)

Table 15: Total Diagnosed cases of Herpetic Keratitis in France (2017-2028)

Table 16: Incidence of Herpetic Keratitis by types in France (2017-2028)

Table 17: Incidence of Epithelial Keratitis by sub-types in France (2017-2028)

Table 18: Incidence of Stromal Keratitis by sub-types in France (2017-2028)

Table 19: Metaherpetic Manifestations of Herpetic Keratitis in France (2017-2028)

Table 20: Total Incident Population of Herpetic Keratitis in Italy (2017-2028)

Table 21: Total Diagnosed cases of Herpetic Keratitis in Italy (2017-2028)

Table 22: Incidence of Herpetic Keratitis by types in Italy (2017-2028)

Table 23: Incidence of Epithelial Keratitis by sub-types in Italy (2017-2028)

Table 24: Incidence of Stromal Keratitis by sub-types in Italy (2017-2028)

Table 25: Metaherpetic Manifestations of Herpetic Keratitis in Italy (2017-2028)

Table 26: Total Incident Population of Herpetic Keratitis in Spain (2017-2028)

Table 27: Total Diagnosed cases of Herpetic Keratitis in Spain (2017-2028)

Table 28: Incidence of Herpetic Keratitis by types in Spain (2017-2028)

Table 29: Incidence of Epithelial Keratitis by sub-types in Spain (2017-2028)

Table 30: Incidence of Stromal Keratitis by sub-types in Spain (2017-2028)

Table 31: Metaherpetic Manifestations of Herpetic Keratitis in Spain (2017-2028)

Table 32: Total Incident Population of Herpetic Keratitis in UK (2017-2028)

Table 33: Total Diagnosed cases of Herpetic Keratitis in UK (2017-2028)

Table 34: Incidence of Herpetic Keratitis by types in UK (2017-2028)

Table 35: Incidence of Epithelial Keratitis by sub-types in UK (2017-2028)

Table 36: Incidence of Stromal Keratitis by sub-types in UK (2017-2028)

Table 37: Metaherpetic Manifestations of Herpetic Keratitis in UK (2017-2028)

Table 38: Total Incident Population of Herpetic Keratitis in Japan (2017-2028)

Table 39: Total Diagnosed cases of Herpetic Keratitis in Japan (2017-2028)

Table 40: Incidence of Herpetic Keratitis by types in Japan (2017-2028)

Table 41: Incidence of Epithelial Keratitis by sub-types in Japan (2017-2028)

Table 42: Incidence of Stromal Keratitis by sub-types in Japan (2017-2028)

Table 43: Metaherpetic Manifestations of Herpetic Keratitis in Japan (2017-2028)

Table 44: 7 Major Market Size of Herpetic Keratitis in USD Million (2017-2028)

Table 45: United States Market Size of Herpetic Keratitis in the US, USD Million (2017-2028)

Table 46: Market Size of Herpetic Keratitis by Line of Therapies in the US, in USD Million (2017-2028)

Table 47: Market Size of Herpetic Keratitis in Germany, in USD Million (2017-2028)

Table 48: Market Size of Herpetic Keratitis by Line of Therapies in Germany, in USD Million (2017-2028)

Table 49: Market Size of Herpetic Keratitis in France, in USD Million (2017-2028)

Table 50: Market Size of Herpetic Keratitis by Line of Therapies in France, in USD Million (2017-2028)

Table 51: Market Size of Herpetic Keratitis in Italy, in USD Million (2017-2028)

Table 52: Market Size of Herpetic Keratitis by Line of Therapies in Italy, in USD Million (2017-2028)

Table 53: Market Size of Herpetic Keratitis in Spain, in USD Million (2017-2028)

Table 54: Market Size of Herpetic Keratitis by Line of Therapies in Spain, in USD Million (2017-2028)

Table 55: Market Size of Herpetic Keratitis in the UK, in USD Million (2017-2028)

Table 56: Market Size of Herpetic Keratitis by Line of Therapies in the UK, in USD Million (2017-2028)

Table 57: Market Size of Herpetic Keratitis in Japan, in USD Million (2017-2028)

Table 58: Market Size of Herpetic Keratitis by Line of Therapies in Japan, in USD Million (2017-2028)

Figure 1: Total Diagnosed Patient Population of Herpetic Keratitis in the 7MM (2017-2028)

Figure 2: Total Prevalence of Herpetic Keratitis in the United States (2017-2028)

Figure 3: Total Diagnosed cases of Herpetic Keratitis in the United States (2017-2028)

Figure 4: Incidence of Herpetic Keratitis by types in the United States (2017-2028)

Figure 5: Incidence of Epithelial Keratitis by sub-types in the United States (2017-2028)

Figure 6: Incidence of Stromal Keratitis by sub-types in the United States (2017-2028)

Figure 7: Metaherpetic Manifestations of Herpetic Keratitis in the United States (2017-2028)

Figure 8: Total Prevalence of Herpetic Keratitis in Germany (2017-2028)

Figure 9: Total Diagnosed cases of Herpetic Keratitis in Germany (2017-2028)

Figure 10: Incidence of Herpetic Keratitis by types in Germany (2017-2028)

Figure 11: Incidence of Epithelial Keratitis by sub-types in Germany (2017-2028)

Figure 12: Incidence of Stromal Keratitis by sub-types in Germany (2017-2028)

Figure 13: Metaherpetic Manifestations of Herpetic Keratitis in Germany (2017-2028)

Figure 14: Total Prevalence of Herpetic Keratitis in France (2017-2028)

Figure 15: Total Diagnosed cases of Herpetic Keratitis in France (2017-2028)

Figure 16: Incidence of Herpetic Keratitis by types in France (2017-2028)

Figure 17: Incidence of Epithelial Keratitis by sub-types in France (2017-2028)

Figure 18: Incidence of Stromal Keratitis by sub-types in France (2017-2028)

Figure 19: Metaherpetic Manifestations of Herpetic Keratitis in France (2017-2028)

Figure 20: Total Prevalence of Herpetic Keratitis in Italy (2017-2028)

Figure 21: Total Diagnosed cases of Herpetic Keratitis in Italy (2017-2028)

Figure 22: Incidence of Herpetic Keratitis by types in Italy (2017-2028)

Figure 23: Incidence of Epithelial Keratitis by sub-types in Italy (2017-2028)

Figure 24: Incidence of Stromal Keratitis by sub-types in Italy (2017-2028)

Figure 25: Metaherpetic Manifestations of Herpetic Keratitis in Italy (2017-2028)

Figure 26: Total Prevalence of Herpetic Keratitis in Spain (2017-2028)

Figure 27: Total Diagnosed cases of Herpetic Keratitis in Spain (2017-2028)

Figure 28: Incidence of Herpetic Keratitis by types in Spain (2017-2028)

Figure 29: Incidence of Epithelial Keratitis by sub-types in Spain (2017-2028)

Figure 30: Incidence of Stromal Keratitis by sub-types in Spain (2017-2028)

Figure 31: Metaherpetic Manifestations of Herpetic Keratitis in Spain (2017-2028)

Figure 32: Total Prevalence of Herpetic Keratitis in UK (2017-2028)

Figure 33: Total Diagnosed cases of Herpetic Keratitis in UK (2017-2028)

Figure 34: Incidence of Herpetic Keratitis by types in UK (2017-2028)

Figure 35: Incidence of Epithelial Keratitis by sub-types in UK (2017-2028)

Figure 36: Incidence of Stromal Keratitis by sub-types in UK (2017-2028)

Figure 37: Metaherpetic Manifestations of Herpetic Keratitis in UK (2017-2028)

Figure 38: Total Prevalence of Herpetic Keratitis in Japan (2017-2028)

Figure 39: Total Diagnosed cases of Herpetic Keratitis in Japan (2017-2028)

Figure 40: Incidence of Herpetic Keratitis by types in Japan (2017-2028)

Figure 41: Incidence of Epithelial Keratitis by sub-types in Japan (2017-2028)

Figure 42: Incidence of Stromal Keratitis by sub-types in Japan (2017-2028)

Figure 43: Metaherpetic Manifestations of Herpetic Keratitis in Japan (2017-2028)

Figure 44: Unmet Needs of Herpetic Keratitis

Figure 45: 7 Major Market Size of Herpetic Keratitis in USD Million (2017-2028)

Figure 46: Market Size of Herpetic Keratitis in the United States, USD Millions (2017-2028)

Figure 47: Market Size of Herpetic Keratitis by Line of Therapies in the US, in USD Million (2017-2028)

Figure 48: Market Size of Herpetic Keratitis in Germany, USD Million (2017-2028)

Figure 49: Market Size of Herpetic Keratitis by Line of Therapies, in Germany, in USD Million (2017-2028)

Figure 50: Market Size of Herpetic Keratitis in France, USD Million (2017-2028)

Figure 51: Market Size of Herpetic Keratitis by Line of Therapies, in France, in USD Million (2017-2028)

Figure 52: Market Size of Herpetic Keratitis in Italy, USD Million (2017-2028)

Figure 53: Market Size of Herpetic Keratitis by Line of Therapies in Italy, in USD Million (2017-2028)

Figure 54: Market Size of Herpetic Keratitis in Spain, USD Million (2017-2028)

Figure 55: Market Size of Herpetic Keratitis by Line of Therapies in Spain, in USD Million (2017-2028)

Figure 56: Market Size of Herpetic Keratitis in the UK, USD Million (2017-2028)

Figure 57: Market Size of Herpetic Keratitis by Line of Therapies in the UK, in USD Million (2017-2028)

Figure 58: Market Size of Herpetic Keratitis in Japan, USD Million (2017-2028)

Figure 59: Market Size of Herpetic Keratitis by Line of Therapies in Japan, in USD Million (2017-2028)

Figure 60: Market Drivers

Figure 61: Market Barriers

  • Tags:
  • Herpetic Keratitis market
  • Herpetic Keratitis market research
  • Herpetic Keratitis market insight
  • Herpetic Keratitis market trends
  • Herpetic Keratitis market forecast
  • Herpetic Keratitis market share
  • Herpetic Keratitis pipeline drugs
  • Herpetic Keratitis treatment algori...
  • Herpetic Keratitis drugs
  • Herpetic Keratitis sales forecastin...
  • Herpetic Keratitis market size
  • Herpetic Keratitis disease
  • Herpetic Keratitis epidemiology
  • Herpetic Keratitis
  • Herpetic Keratitis Companies
  • Herpetic Keratitis Pipeline

Forward to Friend

Need A Quote